Positron emission tomography for assessment of viability

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The recent success of magnetic resonance imaging for viability assessment has raised questions about the future role of positron emission tomography and older imaging modalities in the assessment of viability. Recent information, however, indicates that positron emission tomography will remain a valuable tool. RECENT FINDINGS: The primary positron emission tomography tracer used for assessment of viability is F-fluorodeoxyglucose, a glucose analogue that exhibits enhanced uptake in ischemic tissue. The finding of enhanced F-fluorodeoxyglucose uptake and a relative reduction in perfusion is considered the positron emission tomography correlate of myocardial hibernation. The mismatch pattern has been shown to identify patients with improvement in systolic function, heart failure symptoms, and prognosis with revascularization. Mismatch identifies a subset of patients with vulnerable myocardium who have a higher likelihood of a cardiac event compared with those without significant mismatch. Delay in revascularization may pose extra risk for those with mismatch. Positron emission tomography and magnetic resonance imaging demonstrate a close correlation in the detection of viable myocardium. The development of combined positron emission tomography/computed tomography scanners can reduce imaging time and improve functional-anatomic correlations. SUMMARY: Positron emission tomography imaging utilizing F-fluorodeoxyglucose and perfusion tracers provides valuable diagnostic and prognostic information in patients with ischemic left ventricular dysfunction and has comparable accuracy to competing technologies for detection of viability.

Original languageEnglish
Pages (from-to)464-468
Number of pages5
JournalCurrent Opinion in Cardiology
Volume21
Issue number5
DOIs
StatePublished - Sep 2006

Fingerprint

Positron-Emission Tomography
Myocardium
Perfusion
Magnetic Resonance Imaging
X-Ray Computed Tomography Scanners
Myocardial Stunning
Systolic Heart Failure
Left Ventricular Dysfunction
Technology
Glucose

Keywords

  • Coronary artery disease
  • Myocardial viability
  • Positron emission tomography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Positron emission tomography for assessment of viability. / Sawada, Stephen.

In: Current Opinion in Cardiology, Vol. 21, No. 5, 09.2006, p. 464-468.

Research output: Contribution to journalArticle

@article{677ea009b7634292b3568abf2b5c4133,
title = "Positron emission tomography for assessment of viability",
abstract = "PURPOSE OF REVIEW: The recent success of magnetic resonance imaging for viability assessment has raised questions about the future role of positron emission tomography and older imaging modalities in the assessment of viability. Recent information, however, indicates that positron emission tomography will remain a valuable tool. RECENT FINDINGS: The primary positron emission tomography tracer used for assessment of viability is F-fluorodeoxyglucose, a glucose analogue that exhibits enhanced uptake in ischemic tissue. The finding of enhanced F-fluorodeoxyglucose uptake and a relative reduction in perfusion is considered the positron emission tomography correlate of myocardial hibernation. The mismatch pattern has been shown to identify patients with improvement in systolic function, heart failure symptoms, and prognosis with revascularization. Mismatch identifies a subset of patients with vulnerable myocardium who have a higher likelihood of a cardiac event compared with those without significant mismatch. Delay in revascularization may pose extra risk for those with mismatch. Positron emission tomography and magnetic resonance imaging demonstrate a close correlation in the detection of viable myocardium. The development of combined positron emission tomography/computed tomography scanners can reduce imaging time and improve functional-anatomic correlations. SUMMARY: Positron emission tomography imaging utilizing F-fluorodeoxyglucose and perfusion tracers provides valuable diagnostic and prognostic information in patients with ischemic left ventricular dysfunction and has comparable accuracy to competing technologies for detection of viability.",
keywords = "Coronary artery disease, Myocardial viability, Positron emission tomography",
author = "Stephen Sawada",
year = "2006",
month = "9",
doi = "10.1097/01.hco.0000240583.91591.a8",
language = "English",
volume = "21",
pages = "464--468",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Positron emission tomography for assessment of viability

AU - Sawada, Stephen

PY - 2006/9

Y1 - 2006/9

N2 - PURPOSE OF REVIEW: The recent success of magnetic resonance imaging for viability assessment has raised questions about the future role of positron emission tomography and older imaging modalities in the assessment of viability. Recent information, however, indicates that positron emission tomography will remain a valuable tool. RECENT FINDINGS: The primary positron emission tomography tracer used for assessment of viability is F-fluorodeoxyglucose, a glucose analogue that exhibits enhanced uptake in ischemic tissue. The finding of enhanced F-fluorodeoxyglucose uptake and a relative reduction in perfusion is considered the positron emission tomography correlate of myocardial hibernation. The mismatch pattern has been shown to identify patients with improvement in systolic function, heart failure symptoms, and prognosis with revascularization. Mismatch identifies a subset of patients with vulnerable myocardium who have a higher likelihood of a cardiac event compared with those without significant mismatch. Delay in revascularization may pose extra risk for those with mismatch. Positron emission tomography and magnetic resonance imaging demonstrate a close correlation in the detection of viable myocardium. The development of combined positron emission tomography/computed tomography scanners can reduce imaging time and improve functional-anatomic correlations. SUMMARY: Positron emission tomography imaging utilizing F-fluorodeoxyglucose and perfusion tracers provides valuable diagnostic and prognostic information in patients with ischemic left ventricular dysfunction and has comparable accuracy to competing technologies for detection of viability.

AB - PURPOSE OF REVIEW: The recent success of magnetic resonance imaging for viability assessment has raised questions about the future role of positron emission tomography and older imaging modalities in the assessment of viability. Recent information, however, indicates that positron emission tomography will remain a valuable tool. RECENT FINDINGS: The primary positron emission tomography tracer used for assessment of viability is F-fluorodeoxyglucose, a glucose analogue that exhibits enhanced uptake in ischemic tissue. The finding of enhanced F-fluorodeoxyglucose uptake and a relative reduction in perfusion is considered the positron emission tomography correlate of myocardial hibernation. The mismatch pattern has been shown to identify patients with improvement in systolic function, heart failure symptoms, and prognosis with revascularization. Mismatch identifies a subset of patients with vulnerable myocardium who have a higher likelihood of a cardiac event compared with those without significant mismatch. Delay in revascularization may pose extra risk for those with mismatch. Positron emission tomography and magnetic resonance imaging demonstrate a close correlation in the detection of viable myocardium. The development of combined positron emission tomography/computed tomography scanners can reduce imaging time and improve functional-anatomic correlations. SUMMARY: Positron emission tomography imaging utilizing F-fluorodeoxyglucose and perfusion tracers provides valuable diagnostic and prognostic information in patients with ischemic left ventricular dysfunction and has comparable accuracy to competing technologies for detection of viability.

KW - Coronary artery disease

KW - Myocardial viability

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=33747052580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747052580&partnerID=8YFLogxK

U2 - 10.1097/01.hco.0000240583.91591.a8

DO - 10.1097/01.hco.0000240583.91591.a8

M3 - Article

C2 - 16900009

AN - SCOPUS:33747052580

VL - 21

SP - 464

EP - 468

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 5

ER -